CBN in France: legal status and 2 sleep trials

Cannabinol was the first cannabinoid ever isolated. A 2021 review in Frontiers in Pharmacology notes that it was extracted in 1896 from Indian hemp, and that its structure was worked out in the 1940s. For a long time it was believed to cause the effects of cannabis, until THC was identified.

The same review makes a point many product pages leave out: the plant does not synthesise CBN. It comes from the breakdown of Δ⁹-THC, which heat and ultraviolet light convert little by little. A fresh flower therefore contains very little. A flower or resin stored for a long time, exposed to air and light, builds up more as its THC declines.

At the receptor level, CBN is a weak partial agonist. According to the 2021 review, it binds less well than THC to the CB1 and CB2 receptors, and it is less potent than THC at CB1, the receptor behind the psychoactive effect.

Our article CBD or CBN goes through the chemical comparison between the two molecules.

CBN is not on any narcotics list. Do not confuse it with the semi-synthetic molecules the ANSM, the French medicines agency, has classified: HHC and two derivatives from 13 June 2023, then H4CBD, THCP and other derivatives from 3 June 2024. A "CBN" product containing any of them would fall under those decisions.

A product containing CBN must also respect the hemp framework: the order of 30 December 2021 caps Δ⁹-THC at 0.30%. A CBN-rich extract comes from degraded THC, so the remaining THC level has to be checked on the certificate of analysis.

The deciding question is ingestion. On 20 May 2026 the Ministry of Agriculture published a statement titled "Foods containing cannabidiol (CBD): illegal products that must be withdrawn from the market". It covers foods containing CBD or other extracted cannabinoids, food supplements included, on the basis of the EU novel food regulation. A CBN gummy, capsule or oil to swallow is therefore caught by the same ban as its CBD equivalent. Gummies that combine CBN and THC raise a narcotics problem on top of that: our article on CBN + THC gummies explains why.

The "sleep cannabinoid" reputation came before the data. The 2021 review cited above still found little evidence of a CBN effect on sleep. Two randomised, placebo-controlled trials have been published since.

The first trial, published in Experimental and Clinical Psychopharmacology, compared a placebo, 20 mg of CBN alone and three CBN + CBD combinations (10, 20 or 100 mg of CBD). CBN alone reduced the number of awakenings and the overall sleep disturbance score. Adding CBD improved nothing. Neither the time to fall asleep nor next-day fatigue changed.

The second trial, published in 2026 in the Journal of Sleep Research, measured more rigorously but was tiny. At 300 mg, fifteen times the dose of the earlier trial, CBN shortened sleep onset by 7 minutes and slightly reduced arousals. At 30 mg, nothing changed. The authors list the limits themselves: 20 participants, one night, many outcomes tested.

These results do not make CBN a sleep aid. No health authority has recognised it as one, and no health claim may accompany its sale. Under Article L5111-1 of the French Public Health Code, a product presented as having curative properties becomes a medicine by presentation. Our review of CBD and sleep does the same exercise for CBD.

France's national health authority, the HAS, describes a three-step approach: sleep hygiene first, then cognitive behavioural therapy, then a sleeping pill as a last resort, for four weeks at most. CBN appears at none of these steps. Lasting insomnia is a matter for a doctor, not a shop shelf.

The first risk of a CBN product lies in what else it contains. In June 2025 the ANSM and ANSES, the French food safety agency, reported several hundred poisonings since 2024 linked to products sold as CBD, most often because of synthetic cannabinoids or THC above 0.3%. Both agencies also point out that CBD taken with some medicines can reduce their effectiveness or increase their side effects. For CBN, interaction data are missing: the same caution applies, and a pharmacist's advice is needed if you take any treatment.

Pregnant or breastfeeding women and minors are excluded as a precaution. Finally, CBN itself is not what a saliva test looks for, but a full-spectrum hemp extract contains THC. French law penalises driving after narcotic use with no minimum threshold: our article on CBD and driving sets out the penalties since 2025.

On a certificate of analysis, look for four lines: CBN as a percentage or in mg/ml, Δ⁹-THC at 0.30% or less, THCA (which turns back into THC when heated), and the absence of HHC, H4CBD and THCP when the lab tested for them. The batch number must match the one on the bottle. Our guide to the certificate of analysis covers each section, and our laboratory page describes the measurement methods.